Mega-trend:

le opportunità di

crescita del futuro

If the 19th century was the century of chemistry and the 20th the century of physics, we believe the 21st will be the century of biology.

As we unravel secrets about DNA and deploy that knowledge to re-engineer biological systems, we believe revolutionary advances will continually transform industries from healthcare, agriculture and manufacturing to energy production, consumer services and data storage creating a historic investment opportunity. To help investors capitalize, we leveraged the insights of futurist Jamie Metzl, member of the World Health Organization’s expert committee on human genome edit, to launch a revolutionary new ETF, the WisdomTree BioRevolution Fund UCITS ETF (WDNA).

RELATED LINKS

The Case for WisdomTree BioRevolution UCITS ETF

Presentation: WisdomTree BioRevolution UCITS ETF

Invest in the Power of Innovation

The biology revolution is rapidly improving our ability to understand, read, write, and hack DNA, the genetic code of all life. Learn how the WisdomTree BioRevolution Fund (WDNA) can help capitalize on this megatrend.

Play Icon

Augmented Humanity

Jamie Metzl (WCIT 2019)

Driven by connectivity and today’s exponential advances in knowledge, science has given us the capacity to be Gods over our species. The question is, how do we we optimize the benefits and minimize the risks? Hear the fascinating facts from futurist Jamie Metzl, whose insights helped us create the new WisdomTree BioRevolution UCITS ETF (WDNA).

Are You Ready for the Genetic Revolution?

Jamie Metzl (TEDxPaloAlto)

DNA sequencing is at the core of the BioRevolution. In this thought-provoking TED Talk, renowned futurist and thought leader on the BioRevolution, Jamie Metzl, breaks down the how’s, why’s and what-if’s of the genetic revolution that is transforming this century. WisdomTree partnered with Jamie to shape WisdomTree BioRevolution UCITS ETF (WDNA).

Statements concerning trends in the fields, industries and sectors discussed are based on current conditions, which will fluctuate. References to specific securities and their issuers are for illustrative purposes only and are not intended to be, and should not be interpreted as, recommendations to purchase or sell such securities. This material represents an assessment of trends discussed at a specific time and is not intended to be a forecast of future events or a guarantee of future results. This material should not be relied upon as research or investment advice regarding any security in particular. The user of this information assumes the entire risk of any use made of the information provided herein.

Bloomberg Businessweek Podcast:
Investing in the BioRevolution Megatrend

Jeremy Schwartz, Global Head of Research at Wisdomtree and Jamie Metzl, Senior Fellow at the Atlantic Council, discuss launching their BioRevolution Fund to invest in multiple fields including vaccines, agriculture and big data analytics.

 

For a list of Fund holdings, visit the WDNA product page.

Our BioRevolution UCITS ETF

WDNA
WisdomTree BioRevolution Fund
The WisdomTree BioRevolution UCITS ETF (WDNA) provides targeted exposure to companies that have the potential to be significantly transformed by advancements in genetics and biotechnology.

Latest megatrend insights

2024 Superconvergence BioRevolution Series: Training the Immune System to Fight Cancer - Cover Image
A Dog, a Diagnosis and a Different Way to Understand AI
Christopher Gannatti, CFA
A single dog’s cancer diagnosis shows how AI can turn biology into a data problem, reshaping what’s possible in medicine. Christopher Gannatti explains how this shift reframes AI investing—spanning everything from mega-cap tech to bio-revolution breakthroughs.
Read the blog post
2024 Superconvergence BioRevolution Series: Training the Immune System to Fight Cancer - Cover Image
Beyond the Buzz—Segmenting AI Exposure
Christopher Gannatti, CFA
AI is reshaping industries far beyond tech, and broad ETFs may miss the mark. Christopher Gannatti explains how WisdomTree’s six specialized Funds segment AI exposure across cybersecurity, biotech, cloud and more, helping investors to truly align with the component of the AI economy for which they are seeking exposure.
Read the blog post
Diverging Paths: A Look at WisdomTree’s Best and Worst ETFs in Q1 2025
Christopher Gannatti, CFA
In developed international equities, with a tougher period for equities in 2025 value and high dividends have delivered relative outperformance. Christopher Gannatti unpacks why the early 2025 outperformance of the WisdomTree International High Dividend Fund signals a shift in investor sentiment and how sector tilts and yield dynamics set it apart from quality-focused strategies like the WisdomTree International Quality Dividend Growth Fund.
Read the blog post
    For more daily insights from our thought leaders, visit our blog.